Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies

Robert Cross, Chad Mire, Luis M. Branco, Joan B. Geisbert, Megan M. Rowland, Megan L. Heinrich, Augustine Goba, Mambu Momoh, Donald S. Grant, Mohamed Fullah, Sheik Humarr Khan, James E. Robinson, Thomas Geisbert, Robert F. Garry

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively. We previously identified several recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong neutralization profiles in vitro. Here, we demonstrate remarkable therapeutic efficacy using first-in-class human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment alternative.

Original languageEnglish (US)
Pages (from-to)218-222
Number of pages5
JournalAntiviral Research
Volume133
DOIs
StatePublished - Sep 1 2016

ASJC Scopus subject areas

  • Pharmacology
  • Virology

Fingerprint Dive into the research topics of 'Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies'. Together they form a unique fingerprint.

  • Cite this

    Cross, R., Mire, C., Branco, L. M., Geisbert, J. B., Rowland, M. M., Heinrich, M. L., Goba, A., Momoh, M., Grant, D. S., Fullah, M., Khan, S. H., Robinson, J. E., Geisbert, T., & Garry, R. F. (2016). Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antiviral Research, 133, 218-222. https://doi.org/10.1016/j.antiviral.2016.08.012